Results 231 to 240 of about 83,183 (296)

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

Identification of Tumor- and Immunosuppression-Driven Glioblastoma Subtypes Characterized by Clinical Prognosis and Therapeutic Targets. [PDF]

Curr Issues Mol Biol
Zhang P, Liu D, Liu X, Fan S, Chen Y, Yu T, Dong L.   +6 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Kidney Transplant Outcomes With Non-Depleting Antibody Induction Therapy in Human Leucocyte Antigen Sensitised Recipients. [PDF]

Transpl Int
Nagpal R, Butler K, Thal N, Hobill A, Gage A, Javed M, Karst F, Khan AA, Needleman A, Shirling G, Stephens H, Vivers S, Tavarozzi F, Mayor N, Frater S, Salama A, Harber M, Jones G, Fernando R, Evans RDR.   +19 more
europepmc   +1 more source

Vasculitic fasciitis characterizes a distinct subset of vasculitic myopathy with interferon-gamma signature. [PDF]

Acta Neuropathol
Ruffer N, Pinal-Fernandez I, Preusse C, Mammen AL, Holzer MT, Kleefeld F, Goebel HH, Casal-Dominguez M, Pak K, Kötter I, Siefert J, Furth C, Feldhaus F, Görl N, Fieber F, Alten R, Huber TB, Casteleyn V, Roos A, Krusche M, Schneider U, Milisenda JC, Stenzel W.   +22 more
europepmc   +1 more source

An integrative algorithm combining HLA epitope registry, PIRCHE-T2, and PIRCHE-B outcomes to improve immunological risk stratification in kidney transplantation. [PDF]

Front Immunol
Zhao H, Kakodkar P, Wang E, Zhang D, Niemann M, Webster D, Pearce T, Shoker A, Keown P, Sherwood K, Wu F, Lewis C, Mostafa A.   +12 more
europepmc   +1 more source

Not all Mismatches Were Created Equal: Empirical Identification of Regions Within HLA-DQ Molecules That Harbor the Highest Immunogenicity. [PDF]

Transplantation
Matias EG, Austin DE, Franca KC, Maguire C, Lockhart JS, Lantz CW, Tambur AR.   +6 more
europepmc   +1 more source

The inflammatory path toward type 1 diabetes begins during pregnancy. [PDF]

Nat Commun
Ahrens AP, Dias R, Hyötyläinen T, Orešič M, Triplett EW, Ludvigsson J.   +5 more
europepmc   +1 more source

Mixed Leucocyte Cultures and Histocompatibility Testing

Journal of the Royal College of Physicians of London, 1968
openaire   +2 more sources

The clinical, serological and myopathological features of a cohort of Chinese patients with inclusion body myositis: a single center analysis. [PDF]

Front Immunol
Qiu H, Yang S, Guo X, Leng Y, Zhao Y, Yu M, Zheng Y, Meng L, Lv H, Deng J, Zhang W, Wang Z, Yuan Y, Gang Q.   +13 more
europepmc   +1 more source